Skip to main content

Table 3 Values for diagnostic utility measures for each of the inflammatory back pain definitions and other features of SpA in relation to the presence of sacroiliitis on MRI and positive HLA-B27 testing

From: Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort

  Sacroiliitis on MRI HLA-B27
Sen Spe LR+ LR− PPV NPV Sen Spe LR+ LR− PPV NPV
IBP definition
Calin criteria 51.5 70.9 1.8 0.7 54.0 68.8 36.3 74.2 1.4 0.9 49.7 62.3
Berlin criteria 72.3 50.5 1.5 0.6 49.2 73.3 64.1 49.3 1.3 0.7 47.1 66.1
ASAS criteria 47.7 77.0 2.1 0.7 57.9 68.9 31.5 80.7 1.6 0.9 53.5 62.3
IBP definition plus other IBP characteristics
Calin + alt. buttock 30.8 94.9 6.0 0.7 80.0 67.4 17.4 86.4 1.3 1.0 51.0 56.3
Calin + NSAIDs 36.2 80.1 1.8 0.8 54.7 65.4 28.5 75.7 1.2 0.9 48.8 56.5
Calin + night 28.0 94.9 5.5 0.8 77.8 67.4 16.2 87.9 1.3 1.0 52.3 56.3
Calin + alt. buttock + night 26.9 94.9 5.3 0.8 77.8 66.2 16.0 88.1 1.3 1.0 52.3 56.3
Calin + alt. buttock + NSAIDs 20.0 96.9 6.5 0.8 81.3 64.6 10.4 91.0 1.2 1.0 48.4 55.5
Calin + Night + NSAIDs 29.2 87.2 2.3 0.8 60.3 65.0 21.5 88.3 1.8 0.9 56.3 61.5
Berlin + Insidious 64.6 62.2 1.7 0.6 53.1 72.6 50.7 53.1 1.1 0.9 46.8 57.0
Berlin + NSAIDs 53.8 68.4 1.7 0.7 53.0 69.1 48.9 66.1 1.4 0.8 50.4 64.7
Berlin + insidious + NSAIDs 47.7 76.0 2.0 0.7 56.9 68.7 34.0 67.2 1.0 1.0 45.8 55.6
ASAS + alt. Buttock 30.8 94.4 5.5 0.7 78.4 94.4 18.1 86.4 1.3 0.9 52.0 56.5
ASAS + NSAIDs 36.9 86.2 2.7 0.7 64.0 67.3 24.4 82.0 1.4 0.9 56.4 61.9
ASAS + stiffness 39.2 81.1 2.1 0.7 58.0 66.8 31.3 76.3 1.3 0.9 51.7 57.7
ASAS + alt. Buttock + NSAIDs 21.5 96.4 6.0 0.8 80.0 64.9 10.7 94.3 1.9 0.9 56.9 94.3
ASAS + stiffness + NSAIDs 28.5 88.8 2.5 0.8 62.7 65.2 19.4 83.1 1.1 1.0 48.3 55.9
ASAS + stiffness + alt. buttock 26.9 94.9 5.3 0.8 77.8 66.2 16.0 88.1 1.3 1.0 52.3 56.3
Other SpA features
Enthesitis 11.5 84.7 0.8 1.0 33.3 59.1 17.8 85.1 1.2 0.9 85.1 45.7
Peripheral arthritis 13.8 90.3 1.4 0.9 48.6 61.2 16.7 87.7 1.4 0.9 87.7 48.9
Dactylitis 23.1 94.4 4.1 0.8 21.4 59.3 4.8 96.9 1.6 09 96.9 52.0
Uveitis 6.2 95.9 1.5 0.9 50.0 60.6 8.1 96.9 2.6 0.9 96.9 64.7
Psoriasis 10.0 88.8 0.9 1.0 37.1 59.8 7.0 83.8 0.4 1.1 83.8 23.5
Inflammatory bowel disease 23.1 96.4 6.4 0.8 30.0 59.8 1.5 94.5 0.3 1.0 94.5 16.0
Family history of SpA 27.7 73.0 1.0 0.9 40.4 60.3 33.7 80.2 1.7 0.8 80.2 54.5
Elevated CRP 40.8 77.5 1.8 0.8 55.1 66.0 38.5 77.1 1.7 0.8 77.1 54.6
HLA-B27 59.7 65.1 1.7 0.6 53.5 70.6
  1. MRI magnetic resonance imaging, HLA-B27 human leucocyte antigen B27, Sen sensitivity, Spe specificity, LR+ positive likelihood ratio, LR− negative likelihood ratio, PPV positive predictive value, NPV negative predictive value, ASAS Assessment of SpondyloArthritis International Society, Alt. alternating, NSAIDs nonsteroidal anti-inflammatory drugs, SpA spondyloarthritis, CRP C-reactive protein